via bnet.com
You’d think that the Onglyza failure would make drug reps selling that product vulnerable to Brennan’s desire for layoffs. But AZ is about to double down on Ong-loser with the launch of an Onglyza-metformin combination drug, Kombiglyze — which, as it turns out, is also a virtual clone of Merck’s own combo pill, Janumet. AZ will need to keep reps on that franchise to launch the new product even though the old product’s return on investment demands they be given pink slips or moved elsewhere.
No comments:
Post a Comment